Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Rituximab treatment in myasthenia gravis

  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%-30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a monoclonal antibody against the CD20 protein that leads to B cell depletion and to the synthesis of new antibody-secreting plasma cells. Although rituximab was created to treat B-cell lymphoma, its use has widely increased to treat autoimmune diseases. In MG, the benefit of rituximab treatment in MuSK-positive patients seems clear, but a high variability in the results of observational studies and even clinical trials has been reported for AChR-positive patients. Moreover, few evidence has been reported in seronegative MG and juvenile MG and some questions about regimen of administration or monitoring strategies, remains open. In this review, we intend to revise the available literature on this topic and resume the current evidence of effectiveness of Rituximab in MG, with special attention to results on every MG subtype, as well as the administration protocols, monitoring strategies and safety profile of the drug.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The transition to motherhood, linking hormones, brain and behaviour

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Pretus, Clara|||0000-0003-2172-1184
  • Paternina-Die, María|||0000-0002-5100-4955
  • Soler Campillo, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Leuner, Benedetta|||0000-0002-8919-6892
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
We are witnessing a stark increase in scientific interest in the neurobiological processes associated with pregnancy and maternity. Convergent evidence suggests that around the time of labour, first-time mothers experience a specific pattern of neuroanatomical changes that are associated with maternal behaviour. Here we provide an overview of the human neurobiological adaptations of motherhood, focusing on the interplay between pregnancy-related steroid and peptide hormones, and neuroplasticity in the brain. We discuss which brain plasticity mechanisms might underlie the structural changes detected by MRI, which hormonal systems are likely to contribute to such neuroanatomical changes and how these brain mechanisms may be linked to maternal behaviour. This Review offers an overarching framework that can serve as a roadmap for future investigations.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

  • Marazuela, Mónica|||0000-0003-1158-9618
  • Martínez-Hernández, Rebeca
  • Marques-Pamies, Manuel
  • Biagetti, Betina|||0000-0002-8837-4343
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

When should the nephrologist think about genetics in patients with glomerular diseases?

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Barros, Xoana|||0000-0001-9690-9769
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Shabaka, Amir|||0000-0001-7039-4701
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Ars, Elisabet|||0000-0002-4118-4358
This review discusses the significance of genetics in diagnosing glomerular diseases. Advances in genetic testing, particularly next-generation sequencing, have improved the accessibility and accuracy of diagnosing monogenic diseases, allowing for targeted gene panels and whole-exome/genome sequencing to identify genetic variants associated with glomerular diseases. Key indicators for considering a genetic cause include the age of onset, extrarenal features, family history, and inconclusive kidney biopsy results. Early-onset diseases, for instance, have a higher likelihood of being genetically caused, while extrarenal manifestations can also suggest an underlying genetic condition. A thorough family history can reveal patterns of inheritance that point to monogenic causes, although complexities like incomplete penetrance, skewed X inactivation and mosaicism can complicate the assessment. Also, autosomal recessive conditions imply asymptomatic parents, making genetic suspicion less likely, while de novo mutations can occur without any family history, further obscuring genetic assessment. Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and depletion, presenting in various forms, including primary, genetic, and secondary FSGS. Accurate classification of FSGS patients based on clinical and histological features is essential for guiding treatment decisions, optimizing therapeutic plans, avoiding unnecessary immunosuppression, and predicting relapse risk after kidney transplantation. Overall, a clinicopathological approach, enriched by genetic testing, offers a precise framework for diagnosis and management in glomerular diseases. Future directions for research and clinical practice include potential advancements in genetic testing and personalized medicine, which could further improve diagnostic precision and individualized treatment strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets

  • Apostolova, Nadezda
  • Vezza, Teresa
  • Muntané, Jordi
  • Rocha, Milagros
  • Victor, Víctor M.
Significance: Type 2 diabetes mellitus, which is related to oxidative stress and mitochondrial dysfunction, is one of the most prevalent diseases in the world. In the past decade, alterations in autophagy have been shown to play a fundamental role in the development and control of type 2 diabetes. Further, mitophagy has been recognized as a key player in eliminating dysfunctional mitochondria in this disease. Recent Advances: Recently, much progress has been made in understanding the molecular events associated with oxidative stress, mitochondrial dysfunction, and alterations in autophagy and mitophagy in type 2 diabetes. Critical Issues: Despite increasing evidence of a relationship between mitochondrial dysfunction, oxidative stress, and alterations of autophagy and mitophagy and their role in the pathophysiolology of type 2 diabetes, effective therapeutic strategies to combat the disease through targeting mitochondria, autophagy, and mitophagy are yet to be implemented. Future Directions: This review provides a wide perspective of the existing literature concerning the complicated interplay between autophagy, mitophagy, and mitochondrial dysfunction in type 2 diabetes. Further, potential therapeutic targets based on these molecular mechanisms are explored. Antioxid. Redox Signal. 39, 278–320., This research was supported by the European Regional Development Fund (ERDF “A way to build Europe”); FISABIO (Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, grants UGP15-220 and UGP-21-236); Generalitat Valenciana (grants PROMETEO/2019/027 and AICO/2021/017); and Spanish Ministry of Science and Innovation (grants CIBERehd CB06/04/0071, PI22/00424, PI22/1009, PI19/0437, and PI19/00838 from Carlos III Health Institute, and grant PID2021-127945OB-I00 funded by MCIN/AEI/10.13.039/501100011033/and by FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NMDARs in Alzheimer's Disease: Between Synaptic and Extrasynaptic Membranes

  • Escamilla, Sergio
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada
N-methyl-D-aspartate receptors (NMDARs) are glutamate receptors with key roles in synaptic communication and plasticity. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs can promote cell death underlying a potential mechanism of neurodegeneration occurring in Alzheimer's disease (AD). The distribution of synaptic versus extrasynaptic NMDARs has emerged as an important parameter contributing to neuronal dysfunction in neurodegenerative diseases including AD. Here, we review the concept of extrasynaptic NMDARs, as this population is present in numerous neuronal cell membranes but also in the membranes of various non-neuronal cells. Previous evidence regarding the membranal distribution of synaptic versus extrasynaptic NMDRs in relation to AD mice models and in the brains of AD patients will also be reviewed., This research was funded by Fondo de Investigaciones Sanitarias (PI22-01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), and the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308). We acknowledge financial support from the Spanish Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (CEX2021-001165-S). Sergio Escamilla is funded by the Instituto Carlos III de Madrid (PFIS fellowship)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Persistent elite controllers as the key model to identify permanent HIV remission

  • Gasca-Capote, Carmen
  • Ruiz-Mateos, Ezequiel
[Purpose of review] To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control., [Recent findings] Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression., [Summary] According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured., This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”, research contracts FI19/00083 and MV20/00057 to C.G.C. and research projects PI19/01127 and PI22/01796 to E.R.M.) and Gilead Fellowships (GLD22/00147 to E.R.M.). E.R.M. was granted by the Spanish National Research Council (CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis

  • Romero-Gómez, Manuel
  • Ferretti, Sebastián
  • Arab, Juan Pablo
[EN] The proposal for a nomenclature changes stems from the inaccuracy of the original term, as well as on the absence of any allusion to metabolic disorders and the stigma generated by the use of the terms “nonalcoholic” and “fatty”. The term thus proposed a change from basing its definition on the existence of a histological lesion typical of alcohol damage in the absence of significant alcohol consumption to being defined by the presence of hepatic steatosis demonstrated through biopsy or imaging methods associated with cardiometabolic risk factors, such as diabetes, obesity, arterial hypertension or dyslipidemia in the absence of pathological alcohol consumption. This change has made it possible to define hepatic steatosis as a disease attributed to metabolic disorder and alcohol. This proves the specific similarities and differences between metabolic hepatic steatosis and alcoholic hepatic steatosis, both in their pathogenesis and in the role of genetics and the intestine-liver axis, as well as in potential therapeutic options such as resmetirom or semaglutide. Likewise, this change has made it possible to classify other specific and rare causes of hepatic steatosis, such as hepatotoxicity, immunogenic diseases, hepatitis C or celiac disease., [ES] La propuesta de cambio de nomenclatura encontraba su razón de ser en la inexactitud del término original, así como en la ausencia de alusión a los trastornos metabólicos que conforman su esencia y al estigma que genera el uso tanto del término «no alcohólico», como del de «graso» (fatty en inglés o gordura en portugués). El término pasó de basar su definición en la existencia de una lesión histológica típica del daño por alcohol en ausencia de consumo significativo a definirse a partir de la presencia de esteatosis hepática demostrada por biopsia o métodos de imagen asociados a factores de riesgo cardiometabólicos, como la diabetes, la obesidad, la hipertensión arterial o la dislipemia en ausencia de consumo patológico de alcohol. Este cambio de la nomenclatura ha permitido definir una nueva entidad, la esteatosis hepática por trastorno metabólico y alcohol (EHmet-ALD) que muestra similitudes y diferencias específicas tanto con la esteatosis hepática metabólica (EHmet) como con la esteatosis hepática alcohólica (EHalc) tanto en la patogenia como en el papel de la genética y el eje intestino-hígado como en las potenciales opciones terapéuticas como resmetirom o semaglutida. De la misma forma, este cambio ha permitido ordenar otras causas específicas y poco frecuentes de esteatosis hepática como la hepatotoxicidad, enfermedades monogénicas, la hepatitis C o la enfermedad celíaca., With thanks to the Research Project PI2201342., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Risk for COVID-19 Vulnerability in Patients with Inflammatory Bowel Disease: Assessing Alterations in ACE2 and TMPRSS2

  • Sáez-Leyva, Jorge
  • Lennol, Matthew P.
  • Avilés-Granados, Carlos
  • García-Ayllón, María-Salud
  • Sáez-Valero, Javier
Chronic inflammatory conditions often involve the dysregulation of key enzymes, including serine proteases such as transmembrane serine protease 2 (TMPRSS2) and the angiotensin converting enzyme 2 (ACE2), which are key proteins implicated in the cellular entry mechanism of SARS-CoV-2. It remains uncertain whether the gastrointestinal symptoms observed in COVID-19 patients result from direct viral infection of the gastrointestinal tract, a process that may be exacerbated by altered expression of ACE2 or TMPRSS2. In this review, we explore the interplay among ACE2 and TMPRSS2 in the context of inflammatory bowel disease (IBD), including their roles in disease pathology and response to therapy. We also examine methodological approaches for assessing whether protease alterations contribute to increased susceptibility to infection, considering that TMPRSS2 exists in inactive (zymogen) and active forms. Furthermore, while membrane-bound ACE2 facilitates viral entry, soluble ACE2 fragments may act as decoys, preventing virus–receptor interaction. Therefore, the interpretation of changes in full-length versus cleaved forms of ACE2 and related enzymes is critical for understanding vulnerability to SARS-CoV-2 infection., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D + I 2021–2023, co-funded by the European Social Fund (FSE)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phage Therapy for Bone and Joint Infections: Towards Clinical Translation

  • Ortiz-Cartagena, Concha
  • Blasco, Lucía
  • Bleriot, Inés
  • Esteban, Jaime
  • Toro, María Dolores del
  • Pozo, José Luis del
  • Tomás, María
This article belongs to the Special Issue Bone and Joint Infections: The Challenges of Prevention, Diagnosis and Treatment and Opportunities for Future Research., Osteoarticular infections (OAIs), including osteomyelitis, septic arthritis, prosthetic joint infections, and facture-related infections, remain a major challenge due to biofilm formation and the prevalence of multidrug-resistant (MDR) pathogens. Although OAIs are predominantly caused by Staphylococcus aureus and coagulase-negative staphylococci, the increasing incidence of MDR Gram-negative infections adds further complexity to their management. Standard approaches, combining surgery and prolonged antibiotic therapy, frequently result in recurrence and poor outcomes. Bacteriophage (phage) therapy has emerged as a promising adjunct or alternative approach, offering high host specificity, replication at the infection site, and activity against biofilm-embedded bacteria. This review highlights recent advances in phage therapy for OAIs, focusing on administration routes (intravenous, intra-articular, topical, and oral) and on novel pharmaceutical delivery systems such as hydrogels, bone cements, microparticles, nanoparticles, and implant coatings. Preclinical and early clinical studies have analyzed phage stability, controlled release, and the synergistic effects of combined phage/antibiotic therapy. However, challenges remain regarding standardization, immunogenicity, and regulatory approval. Nonetheless, phage therapy shows promise for clinical translation as an adjunct or alternative to conventional treatments for OAIs. Well-designed clinical trials are urgently needed to confirm the efficacy of phage therapy, optimize delivery strategies, and integrate the treatments in routine practice. Despite encouraging outcomes for a successful clinical implementation, regulation and standardization of GMP production are required., This study was funded by grant PI22/00323 awarded to M. Tomás and PI awarded to Rafael Cantón PI19/01043 within the State Plan for R + D + I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III FEDER, and by a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092 and COOPERA Project, COOP24CIII/00009), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGeneration European Union funds that support the actions of the Resilience and Recovery Facility., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

  • Calvete, Oriol|||0000-0002-2623-2876
  • Mestre, Julia|||0000-0002-4809-3897
  • Jerez, Andrés|||0000-0002-2079-6638
  • Sole, F|||0000-0002-3251-2161
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications

  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Salas, María Queralt|||0000-0003-4567-3682
  • Escribano Serrat, Silvia|||0000-0001-9499-8999
  • Rovira Argelagués, Montserrat|||0000-0001-7786-9079
  • Guillén-Olmos, Elena
  • Fernandez, Sara
  • Ventosa-Capell, Helena
  • Youssef, Lina|||0000-0002-0554-5507
  • Crispi, Fatima|||0000-0002-7422-5240
  • Nomdedeu, Meritxell
  • Martínez Sánchez, Julia
  • De Moner, Blanca
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
The endothelium is a biologically active interface with multiple functions, some of them common throughout the vascular tree, and others that depend on its anatomical location. Endothelial cells are continually exposed to cellular and humoral factors, and to all those elements (biological, chemical, or hemodynamic) that circulate in blood at a certain time. It can adapt to different stimuli but this capability may be lost if the stimuli are strong enough and/or persistent in time. If the endothelium loses its adaptability it may become dysfunctional, becoming a potential real danger to the host. Endothelial dysfunction is present in multiple clinical conditions, such as chronic kidney disease, obesity, major depression, pregnancy-related complications, septic syndromes, COVID-19, and thrombotic microangiopathies, among other pathologies, but also in association with cell therapies, such as hematopoietic stem cell transplantation and treatment with chimeric antigen receptor T cells. In these diverse conditions, evidence suggests that the presence and severity of endothelial dysfunction correlate with the severity of the associated disease. More importantly, endothelial dysfunction has a strong diagnostic and prognostic value for the development of critical complications that, although may differ according to the underlying disease, have a vascular background in common. Our multidisciplinary team of women has devoted many years to exploring the role of the endothelium in association with the mentioned diseases and conditions. Our research group has characterized some of the mechanisms and also proposed biomarkers of endothelial damage. A better knowledge would provide therapeutic strategies either to prevent or to treat endothelial dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Background and Aims: Predictors of first-generation somatostatin receptor ligands (fgSRLs) response in acromegaly have been studied for over 30 years, but they are still not recommended in clinical guidelines. Is there not enough evidence to support their use? This systematic review aims to describe the current knowledge of the main predictors of fgSRLs response and discuss their current usefulness, as well as future research directions. Methods: A systematic search was performed in the Scopus and PubMed databases for functional, imaging, and molecular predictive factors. Results: A total of 282 articles were detected, of which 64 were included. Most of them are retrospective studies performed between 1990 and 2023 focused on the predictive response to fgSRLs in acromegaly. The usefulness of the predictive factors is confirmed, with good response identified by the most replicated factors, specifically low GH nadir in the acute octreotide test, T2 MRI hypointensity, high Somatostatin receptor 2 (SSTR2) and E-cadherin expression, and a densely granulated pattern. Even if these biomarkers are interrelated, the association is quite heterogeneous. With classical statistical methods, it is complex to define reliable and generalizable cut-off values worth recommending in clinical guidelines. Machine-learning models involving omics are a promising approach to achieve the highest accuracy values to date. Conclusions: This survey confirms a sufficiently robust level of evidence to apply knowledge of predictive factors for greater efficiency in the treatment decision process. The irruption of artificial intelligence in this field is providing definitive answers to such long-standing questions that may change clinical guidelines and make personalized medicine a reality.